Dose-dependent efficacy of miglitol, an alfa-glucosidase inhibitor, in type 2 diabetic patients: results of a 24-week double-blind placebo-controlled study.

M.L. Drent, A.T.M. Tollefsen, F.H.J.A. van Heusden, E.B.M. Hoenderdos, J.J.C. Jonker, E.A. van der Veen

Research output: Contribution to JournalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)152-159
JournalDiabetes, Nutrition and Metabolism, Clinical and Experimental
Publication statusPublished - 2002

Cite this